Atropos Health forms Life Science Advisory Board with pharma industry experts

By Liza Laws

- Last updated on GMT

© Getty Images
© Getty Images

Related tags Drug development Drug discovery Research Patient centricity Pharmaceutical industry

A Life Sciences Advisory Board has been launched by Atropos Health, a company that translates data into personalized real-world insights across healthcare.

The life sciences advisory board indicates a continued focus on regulatory complaint and transparent methods for rapid and responsible acceleration of innovation for life science partners on the Evidence Network.

The board will consist of executives from the world’s preeminent pharma companies including Moderna, Novartis among others.

This latest announcement comes hot on the heels of Atropos Health launching Geneva OS (Generative Evidence Acceleration Operating System) and ChatRWD (Real World Data) application​, the first Generative AI application incorporating direct Chat-to-Database capability, to help healthcare and life science leaders advance and accelerate evidence generation.

“I firmly believe that 2024 will be a revolutionary year in drug discovery and the acceleration of early drug development following the heels of innovation in AI,” said Brigham Hyde, co-founder and CEO, of Atropos Health.

“That’s why we’ve pulled together the brightest minds and the most effective companies in life sciences in order to supply organizations with the technology, data, and insights to bridge the evidence gap and bring more drugs to market.”

Members of the board include Barbara Salami, former vice president at Moderna and Gabriel Eichler, founder and managing director of Oak Health Partners, formerly of Novartis. They join Sean Khozin of Braven and Phyusion and Gerry McDougall former senior healthcare consulting partner at PwC.

Collaborating closely with Atropos Health's partners, these advisory board members will spearhead the advocacy for Geneva OS and the Atropos Evidence Network to deliver auditable real-time insights ​​and support safe and compliant access to data across a federated network.

“By dismantling barriers to accessing data and fostering an exchange of observational insights, Atropos Health is redefining life science clinical trials’ research and delivery,” said Salami. “As members of the advisory board, we are advocates of evidence-based medicine, and believe the importance of personalization of each clinical decision in our sector must not be underestimated.”

“The Life Sciences Advisory Board directly complements Atropos Health’s Clinical Advisory Board, which was formed in March to enhance the company’s ability to leverage data into actionable clinical, operational, and financial insights for health system use,” Eichler added. “By democratizing access to essential data, Atropos Health is putting its insight potential into everyone’s hands and leading a powerful paradigm shift.”

Atropos Health is the developer of Geneva OS, the operating system for rapid healthcare evidence across a vast network of real-world data. Health systems and life science companies work with Atropos to close evidence gaps from bench to bedside, elevate clinical outcomes with data-driven care, expedite research.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us